Panagiotis Neofytos currently serves as the Director of Marketing for Oncology at MSD, where he leverages over 18 years of specialized experience in the oncology sector, with a strong focus on immuno-oncology. His extensive background includes more than 12 years of regional experience, allowing him...
Panagiotis Neofytos currently serves as the Director of Marketing for Oncology at MSD, where he leverages over 18 years of specialized experience in the oncology sector, with a strong focus on immuno-oncology. His extensive background includes more than 12 years of regional experience, allowing him to navigate the complexities of the pharmaceutical landscape across diverse markets. In his current role, Panagiotis leads the marketing strategy for KEYTRUDA, specifically targeting melanoma and head and neck squamous cell carcinoma (HNSCC) in the EMEAC region. His strategic oversight ensures that the product not only meets regulatory standards but also effectively addresses the unique needs of patients and healthcare providers in various countries.
Panagiotis’s expertise in market access and product launch is complemented by his robust people management skills, having successfully led cross-functional teams in both local and matrix global environments. His ability to foster collaboration among stakeholders has been instrumental in driving successful commercialization strategies, enhancing the visibility and uptake of innovative therapies. With an International MBA and a B.Sc. in Pharmacy, he combines clinical knowledge with business acumen, positioning him as a thought leader in the oncology marketing space.
Key projects under his leadership have included the development of targeted campaigns that resonate with healthcare professionals and patients alike, as well as initiatives aimed at improving access to life-saving treatments. Panagiotis’s commitment to advancing oncology care is evident in his strategic vision and execution, making him a pivotal figure in MSD’s mission to transform cancer treatment and improve patient outcomes across the EMEAC region.
